Cargando…
Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
BACKGROUND: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). RESULTS: HT(–) and RILA(high) were the two independent factors associated with impr...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884662/ https://www.ncbi.nlm.nih.gov/pubmed/29644007 http://dx.doi.org/10.18632/oncotarget.24606 |
_version_ | 1783311860605386752 |
---|---|
author | Bourgier, Céline Castan, Florence Riou, Olivier Nguyen, Tan-Dat Peignaux, Karine Lemanski, Claire Lagrange, Jean-Léon Kirova, Youlia Lartigau, Eric Belkacemi, Yazid Rivera, Sofia Noël, Georges Clippe, Sébastien Mornex, Françoise Hennequin, Christophe Gourgou, Sophie Brengues, Muriel Fenoglietto, Pascal Ozsahin, Esat Mahmut Azria, David |
author_facet | Bourgier, Céline Castan, Florence Riou, Olivier Nguyen, Tan-Dat Peignaux, Karine Lemanski, Claire Lagrange, Jean-Léon Kirova, Youlia Lartigau, Eric Belkacemi, Yazid Rivera, Sofia Noël, Georges Clippe, Sébastien Mornex, Françoise Hennequin, Christophe Gourgou, Sophie Brengues, Muriel Fenoglietto, Pascal Ozsahin, Esat Mahmut Azria, David |
author_sort | Bourgier, Céline |
collection | PubMed |
description | BACKGROUND: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). RESULTS: HT(–) and RILA(high) were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILA(low) and HT(+) than in patients with RILA(high) and HT(–) (75.8% and 100%, respectively; p = 0.004, hazard ratio 5.84 [95% confidence interval (CI) 1.8–19.1]). Conversely, BFFS at 36 months was comparable in patients with RILA(high) and HT(+) and in patients with RILA(low) and HT(–) (89.8% and 93.5%, respectively; p = 0.39, hazard ratio 1.7 [95% CI 0.51–5.65]), showing that these two parameters influenced independently the occurrence of severe breast fibrosis. BFFS rate was not affected by the HT type (tamoxifen or aromatase inhibitor) and timing (concomitant or sequential with radiotherapy). CONCLUSIONS: HT and RILA score independently influenced BFFS rate at 36 months. Patients with RILA(high) and HT(–) presented an excellent BFFS at 36 months (100%). MATERIALS AND METHODS: Breast Fibrosis-Free Survival (BFFS) rate was assessed relative to RILA categories and to adjuvant HT use (HT(+) and HT(–), respectively) in a prospective multicentre study (NCT00893035) which enrolled 502 breast cancer patients (456 evaluable patients). Breast fibrosis was recorded according to CTCAE v3.0 grading scale; RILA score was defined according to two categories (<12%: RILA(low); ≥12%: RILA(high)). |
format | Online Article Text |
id | pubmed-5884662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58846622018-04-11 Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial Bourgier, Céline Castan, Florence Riou, Olivier Nguyen, Tan-Dat Peignaux, Karine Lemanski, Claire Lagrange, Jean-Léon Kirova, Youlia Lartigau, Eric Belkacemi, Yazid Rivera, Sofia Noël, Georges Clippe, Sébastien Mornex, Françoise Hennequin, Christophe Gourgou, Sophie Brengues, Muriel Fenoglietto, Pascal Ozsahin, Esat Mahmut Azria, David Oncotarget Research Paper BACKGROUND: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). RESULTS: HT(–) and RILA(high) were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILA(low) and HT(+) than in patients with RILA(high) and HT(–) (75.8% and 100%, respectively; p = 0.004, hazard ratio 5.84 [95% confidence interval (CI) 1.8–19.1]). Conversely, BFFS at 36 months was comparable in patients with RILA(high) and HT(+) and in patients with RILA(low) and HT(–) (89.8% and 93.5%, respectively; p = 0.39, hazard ratio 1.7 [95% CI 0.51–5.65]), showing that these two parameters influenced independently the occurrence of severe breast fibrosis. BFFS rate was not affected by the HT type (tamoxifen or aromatase inhibitor) and timing (concomitant or sequential with radiotherapy). CONCLUSIONS: HT and RILA score independently influenced BFFS rate at 36 months. Patients with RILA(high) and HT(–) presented an excellent BFFS at 36 months (100%). MATERIALS AND METHODS: Breast Fibrosis-Free Survival (BFFS) rate was assessed relative to RILA categories and to adjuvant HT use (HT(+) and HT(–), respectively) in a prospective multicentre study (NCT00893035) which enrolled 502 breast cancer patients (456 evaluable patients). Breast fibrosis was recorded according to CTCAE v3.0 grading scale; RILA score was defined according to two categories (<12%: RILA(low); ≥12%: RILA(high)). Impact Journals LLC 2018-03-02 /pmc/articles/PMC5884662/ /pubmed/29644007 http://dx.doi.org/10.18632/oncotarget.24606 Text en Copyright: © 2018 Bourgier et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Bourgier, Céline Castan, Florence Riou, Olivier Nguyen, Tan-Dat Peignaux, Karine Lemanski, Claire Lagrange, Jean-Léon Kirova, Youlia Lartigau, Eric Belkacemi, Yazid Rivera, Sofia Noël, Georges Clippe, Sébastien Mornex, Françoise Hennequin, Christophe Gourgou, Sophie Brengues, Muriel Fenoglietto, Pascal Ozsahin, Esat Mahmut Azria, David Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial |
title | Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial |
title_full | Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial |
title_fullStr | Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial |
title_full_unstemmed | Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial |
title_short | Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial |
title_sort | impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective french trial |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884662/ https://www.ncbi.nlm.nih.gov/pubmed/29644007 http://dx.doi.org/10.18632/oncotarget.24606 |
work_keys_str_mv | AT bourgierceline impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT castanflorence impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT riouolivier impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT nguyentandat impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT peignauxkarine impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT lemanskiclaire impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT lagrangejeanleon impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT kirovayoulia impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT lartigaueric impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT belkacemiyazid impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT riverasofia impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT noelgeorges impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT clippesebastien impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT mornexfrancoise impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT hennequinchristophe impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT gourgousophie impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT brenguesmuriel impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT fenogliettopascal impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT ozsahinesatmahmut impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial AT azriadavid impactofadjuvanthormonotherapyonradiationinducedbreastfibrosisaccordingtotheindividualradiosensitivityresultsofamulticenterprospectivefrenchtrial |